|1.||Saintamand, Alexis: 1 article (08/2015)|
|2.||Cogné, Michel: 1 article (08/2015)|
|3.||Saad, Faten: 1 article (08/2015)|
|4.||Denizot, Yves: 1 article (08/2015)|
|5.||Wang, Yin-Ping: 1 article (04/2015)|
|6.||Yuan, He-Pei: 1 article (04/2015)|
|7.||Ma, Xiao-Bo: 1 article (04/2015)|
|8.||Jiang, Jing: 1 article (04/2015)|
|9.||Zheng, Yan: 1 article (04/2015)|
|10.||Mantuano, Natália Rodrigues: 1 article (01/2015)|
|1.||Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
|2.||T-Cell Leukemia (Leukemia, T Cell)
04/01/1991 - "T-lymphoid cells from patients with chronic T-lymphocytic leukemia, on the other hand, mainly express the tetrasaccharides NeuNAc alpha 2----3Gal beta 1----3(NeuNAc alpha 2----6)GalNAc on leukosialin, but they also express a small significant amount of the hexasaccharides. "
04/01/1991 - "In the present study, we analyzed the structures of O-glycans attached to leukosialin present in various T-lymphocytic leukemia cells. "
04/01/1991 - "T-lymphocytic leukemia expresses complex, branched O-linked oligosaccharides on a major sialoglycoprotein, leukosialin."
|3.||Wiskott-Aldrich Syndrome (Syndrome, Wiskott-Aldrich)
01/01/1993 - "The Wiskott-Aldrich syndrome (WAS) is associated with defective glycosylation and altered membrane expression of the leukocyte sialoglycoprotein CD43. "
07/01/1990 - "Alterations of leukosialin expression have been reported in patients with the Wiskott-Aldrich Syndrome (WAS), an X-chromosome-linked immunodeficiency disease. "
01/01/1990 - "Sialophorin (CD43) and the Wiskott-Aldrich syndrome."
04/01/1989 - "The chromosomal location of the sialophorin gene was determined and the implications of this assignment for the pathogenesis of the Wiskott-Aldrich syndrome are discussed."
04/01/1989 - "Sialophorin (CD43) of leukocytes and platelets is a surface sialoglycoprotein that is phenotypically defective on lymphocytes of patients with the X chromosome-linked immunodeficiency Wiskott-Aldrich syndrome. "
07/01/2012 - "Expression of CD43 (leukosialin), the predominant leukocyte transmembrane sialoglycoprotein, has been detected in many tumors of non-hematopoietic origin. "
09/01/1999 - "Median fluorescence intensity (MFI) of CD43 antigen was 87.7 in the I group comparing to 77.4 in the group II. So one observed tendency to lowering MFI during tumor growing but the difference was not significant (p = 0.25). "
10/01/1993 - "THY 1.1 and CD43 antigen expression on rat tumor cells."
08/21/2015 - "In a 3'RR-deficient background mature tumors less often expressed the CD43 antigen (54% vs 0%, p = 0.02), a membrane glycoprotein expressed on activated mature B-cells. "
01/14/1994 - "Soluble forms of leukosialin or lamp-1 may be useful as therapeutic agents for the inhibition of E-selectin-mediated binding to tumor cells."
03/15/1992 - "Evidence that leukosialin, CD43, is intensely sulfated in the murine T lymphoma line RDM-4."
06/01/1994 - "CD30 antigen was expressed less frequently at clinical stage I than those of stages II to IV. There was no significant relationship between CD30 antigen expression and that of proliferating cell nuclear antigen or CD43 antigen in non-Hodgkin's lymphomas (NHL). "
04/01/2015 - "CD43 (leukosialin) is a transmembrane glycoprotein expressed in a variety of hematopoietic cells, including B lymphocytes, and a variety of malignancies including lymphoma, leukemia, and solid tumors. "
|1.||Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)
|3.||Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)
|8.||Membrane Glycoproteins (Membrane Glycoprotein)